Author:
Di Costanzo F,Carlini P,Doni L,Massidda B,Mattioli R,Iop A,Barletta E,Moscetti L,Recchia F,Tralongo P,Gasperoni S
Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. Alabiso O, Buosi R, Clerico M, Dogliotti L, Forti L, Lattuada S, Merlano M, Ostellino O, Satolli M, Alabiso I, Sponghini A (2001) Preliminary results of a phase II study with gemcitabine and continuous infusion 5-FU in patients with advanced or metastatic pancreatic cancer. Proc Am Soc Clin Oncol 20: A2331
2. Anchisi S, Delaloye B, Petite J, Laurencet FL, Ambrod CH, Obrist R (2000) Gemcitabine (GEM) and continuous infusional 5-FU (Cif) is active and well tolerated in advanced or metastatic pancreatic cancer. Proc Am Soc Clin Oncol 19: A1280H
3. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson 3rd AB (2002) Phase III study of gemcitabine in combination with fluorouracil vs gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20: 3270–3275
4. Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with GEM as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403–2413
5. Cartwright TH, Cohn A, Varkey JA, Chen YM, Szatrowski TP, Cox JV, Schulz JJ (2002) Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 20: 160–164
Cited by
90 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献